2019 Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 102 pages | ID: 2E4CF61837EEN
VPAResearch

Abstracts

The global clinical trial report- “2019 Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Angioimmunoblastic T-Cell Lymphoma (AITL). It presents in-depth analysis of Angioimmunoblastic T-Cell Lymphoma (AITL) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Angioimmunoblastic T-Cell Lymphoma (AITL).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Angioimmunoblastic T-Cell Lymphoma (AITL) clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Angioimmunoblastic T-Cell Lymphoma (AITL)

The research work is prepared through extensive and continuous research on Angioimmunoblastic T-Cell Lymphoma (AITL) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Angioimmunoblastic T-Cell Lymphoma (AITL) patients are identified
• The report includes panorama of Angioimmunoblastic T-Cell Lymphoma (AITL) clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Angioimmunoblastic T-Cell Lymphoma (AITL) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Region
  2.2.2 Average Enrollment of Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Angioimmunoblastic T-Cell Lymphoma (AITL) Treatment, 2019

3. REGION WISE ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) CLINICAL TRIALS

3.1 Asia Pacific Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Country
3.2 Europe Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Country
3.3 North America Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Country
3.4 Middle East and Africa Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Country
3.5 South and Central America Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Country

4. ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) CLINICAL TRIAL TRENDS

4.1 Start Year wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials
4.2 Phase wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials
4.3 Trial Status wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials
4.4 Trial Type wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials

5. ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Angioimmunoblastic T-Cell Lymphoma (AITL) Trials by Year
5.2 Average Enrollment in Angioimmunoblastic T-Cell Lymphoma (AITL) Trials by Phase
5.3 Average Enrollment in Angioimmunoblastic T-Cell Lymphoma (AITL) Trials by Status
5.4 Average Enrollment in Angioimmunoblastic T-Cell Lymphoma (AITL) Trials by Type of Trial

6. COMPANIES PARTICIPATING IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) CLINICAL TRIALS

6.1 Angioimmunoblastic T-Cell Lymphoma (AITL) Trials by Sponsor Type
6.2 Angioimmunoblastic T-Cell Lymphoma (AITL) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Angioimmunoblastic T-Cell Lymphoma (AITL) Trials- Phase
7.2 Angioimmunoblastic T-Cell Lymphoma (AITL) Trials- Phase
7.3 Angioimmunoblastic T-Cell Lymphoma (AITL) Trials- Phase
7.4 Angioimmunoblastic T-Cell Lymphoma (AITL) Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials and Enrolment
Figure 7: North America – Country wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials and Enrolment
Figure 9: Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Phase
Figure 10: Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Trial Status
Figure 11: Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Type
Figure 12: Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Sponsor Type
Figure 13: Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials by Leading Sponsors
Figure 14: Angioimmunoblastic T-Cell Lymphoma (AITL) Average Enrollment by Phase
Figure 15: Angioimmunoblastic T-Cell Lymphoma (AITL) Average Enrollment by Trial Status
Figure 16: Angioimmunoblastic T-Cell Lymphoma (AITL) Average Enrollment by Type
Figure 17: Angioimmunoblastic T-Cell Lymphoma (AITL)- Average Enrolment by Type of Sponsors
Figure 18: Angioimmunoblastic T-Cell Lymphoma (AITL)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials and Enrolment
Table 5: Europe – Country wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials and Enrolment
Table 7: North America – Country wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Angioimmunoblastic T-Cell Lymphoma (AITL) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Angioimmunoblastic T-Cell Lymphoma (AITL) Average Enrollment by Phase
Table 15: Angioimmunoblastic T-Cell Lymphoma (AITL) Average Enrollment by Trial Status
Table 16: Angioimmunoblastic T-Cell Lymphoma (AITL) Average Enrollment by Type
Table 17: Angioimmunoblastic T-Cell Lymphoma (AITL)- Average Enrolment by Type of Sponsors
Table 18: Angioimmunoblastic T-Cell Lymphoma (AITL)- Enrolment by Leading Sponsors